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Abstract
Introduction: Myasthenia gravis is a rare neuromuscular disorder associated with a reduction in the
availability of acetylcholine receptors at the post-synaptic membranes of skeletal muscles. This is
caused by the production of anti-acetylcholine receptor antibodies at the neuromuscular junction due
to an autoimmune insult, leading to a compromised neuromuscular transmission. Verapamil can
influence, in a dose-dependent fashion, the neuromuscular transmission in myasthenia gravis.
Case presentation: We report a 71-year-old Caucasian man with myasthenia gravis suffering from
a cardiogenic shock following a single dose of verapamil. The patient had uncontrolled atrial
fibrillation with a heart rate of 120 beats/min. Atenolol 100 mg was started. The next day, verapamil
SR 240 mg was started. Two hours after the first dose of verapamil, the patient complained of
weakness and dyspnea with signs of shock; his blood pressure was 70/50 mm Hg and heart rate at
101 beats/min. An echocardiogram showed diffuse hypokinesis of both ventricles with an ejection
fraction of 20%. Cardiac catheterization was performed and coronary arteries appeared without
significant stenosis, but there was a diffuse hypokinesis. Verapamil was stopped and the patient
received intravenous glucagon and calcium chloride. Both the anti-acetylcholine receptor and anti-
striated muscle antibodies tested positive. A few hours later, another echocardiogram showed an
improvement in the ventricular function, which returned to normal five days later.
Conclusion: Caution is needed when administering verapamil to patients with myasthenia gravis,
especially when the anti-acetylcholine receptor and anti-striated muscle antibodies titres are positive.
Introduction
Myasthenia gravis (MG) is a rare (4 cases/100,000
individuals) neuromuscular disorder characterized by
weakness and excessive fatigability of skeletal muscles
following repetitive effort and slow recovery after exercise
[1]. The defect in MG is a reduction in the availability of
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skeletal muscles. This is caused by the production of anti-
acetylcholine receptor antibodies (AchR-Ab) at the neuro-
muscular junction (NMJ) due to an auto-immune insult
[2], leading to compromised neuromuscular transmission
(NMT). Verapamil is a calcium channel blocker useful in
lowering blood pressure and in slowing cardiac atrioven-
tricular conduction. It can also affect, in a dose-dependent
fashion, the NMT in MG [3]. Verapamil’s most commonly
reported adverse effects are constipation, dizziness and
nausea. We describe a patient with known MG who
experienced cardiogenic shock following administration
of a dose of verapamil.
Case presentation
A 71-year-old Caucasian male with MG was known to
suffer from nonobstructive hypertrophic cardiomyopathy
and paroxysmal atrial fibrillation and a dilated left atrium.
Multiple unsuccessful electrical and chemical cardiover-
sions (using sotalol and amiodarone) had been attempted
in the past. Therefore, ablation of the AV node was
performed and a permanent dual chamber pacemaker was
implanted. Nonetheless, at the time of admission to
hospital the patient was complaining of fatigue, palpita-
tions and dyspnea that were rapidly linked to uncontrolled
atrial fibrillation at a heart rate of 120/minute. Previously,
for a long time he was on metoprolol 100 mg BID
concomitantly with diltiazem 300 mg OD for heart
rhythm control. To further control the heart rate, he
received in sequence atenolol 100 mg OD and, more than
24 hours after diltiazem cessation, verapamil SR 240 mg
OD to replace his previous regimen. Two hours after
receiving his first dose of verapamil, the patient began to
complain of weakness and dyspnea. He presented with
signs of shock with blood pressure at 70/50 mm Hg and
heart rate at 101/minute. Lung and cardiac auscultation
appeared normal with no new murmur of acute valvular
failure, pulmonary congestion or signs of pulmonary
embolism. An electrocardiogram (ECG) revealed paced
rhythm (Figure 1). A quick bedside echocardiogram
showed diffuse hypokinesis of both ventricles with an
ejection fraction reduced to 20%. Eighteen months before,
an echocardiogram revealed normal left ventricular func-
tion and ejection fraction of 66%. At that time, the
ventricular rate was 110 beats/min while the patient was
on long-acting diltiazem 240 mg OD and cilazapril 5 mg
OD. Cardiac catheterization was performed within min-
utes; coronary arteries appeared without significant
stenosis, but there was a diffuse hypokinesis. At this
point, cardiogenic shock secondary to calcium channel
blocker intoxication was suspected. Blood glucose was
4.3 mmol/L, electrolytes (Na
+,K
+,C l
-) were 138, 5.2, and
105 mmol/L, respectively, all within normal limits. One
hundred percent oxygen administration was per-
formed resulting in a saturation of 98% and a pCO2 to
41.5 mm Hg (normal 35 to 45 mm Hg). Verapamil was
stopped and the patient received intravenous glucagon,
calcium chloride and dopamine. The measure of AchR-Ab
was positive at 0.23 nmol/L (normal ≤0.02 nmol/L) and
the measurement of antistriated muscle antibodies was
also positive at 1:3840 (normal <1:60). A few hours later,
another echocardiogram was performed and there was an
improvement in ventricular function, resulting in recovery
of systolic blood pressure to between 125 and 130 mm
Hg. Five days later, the ejection fraction had returned
to normal as had as the patient’se l e c t r o c a r d i o g r a m
(Figure 1). Re-challenge with verapamil was not per-
formed. The patient died two years later.
Discussion
The histologic striated muscle changes found in MG are
fibre atrophy with varying degrees of inflammation [4]. Of
importance is the fact that antibodies directed against
striated muscle are found in the serum of about one third
of MG patients [5]. Table 1 lists numerous classes of drugs
that have been reported to exacerbate MG.
The calcium channel blocker (CCB) verapamil is useful in
the treatment of recurrent supraventricular arrhythmias.
It blocks the slow calcium ion influx into contractile and
conduction fibres, prolongs the refractory period in nodal
cells and may also depress contractility [6]. Respiratory
failure immediately following intravenous injection of
verapamil has been reported in a patient with Duchenne’s
dystrophy [7]. This suggests that verapamil might exacer-
bate muscle weakness when NMT is impaired. Drug-
induced neuromuscular blockade is uncommon in
subjects without MG, presumably because of the high
safety margin for neuromuscular transmission that exists
under normal circumstances.
Previous studies evaluating theeffects of CCBson the NMT
showed that these agents impair transmission in the NMJ,
especially in conjunction with a second neuromuscular
blocking agent [8]. The safety margin for functional NMT
was reported to be as high as 80% to 90% blockade of all
post-junction receptors [9]. It was reported that MG
muscle showed a 70% to 89% reduction in the number
of acetylcholine receptors per neuromuscular junction,
compared to the control muscle [10], thus strongly
suggesting that verapamil can affect NMT in individuals
with MG at subclinical doses. In other words, the
deleterious neuromuscular action of verapamil in MG is
unmasked by the narrow safety margin resulting in a
reduction in “receptor reserve”. Similarly, verapamil-
induced aggravation of Lambert-Eaton myasthenic syn-
drome has also been described [11]. This might be a
consequence of the effect on voltage-dependent calcium
channels involved in the release of acetylcholine at the
presynaptic nerve terminal, the probable target of the
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(LES) [11].
Indeed, worsening of muscle weakness upon exposure to
verapamil has clearly been demonstrated in disorders of
NMT such as MG and LES [3]. Moreover, it was suggested
that this phenomenon is exacerbated when AchR-Ab and
antistriated muscle antibodies are positive. In our patient,
the measurement of AchR-Ab was positive at 0.23 nmol/L
(normal ≤0.02 nmol/L) and antistriated muscle antibodies
Figure 1. (A) 12-lead electrocardiogram in the Myasthenia Gravis patient two hours after the first dose of verapamil SR
240 mg and just a few minutes before cardiogenic shock. Spectacular widening of the QRS at 230 msec is observed (paper speed:
25 mm/sec). (B) 12-lead electrocardiogram in the Myasthenia Gravis patient in the intensive care unit two hours after verapamil
withdrawal and intravenous administration of calcium chloride and glucagon. Significant hemodynamic improvement was already
observed. QRS narrowing at 138 msec was also seen (paper speed: 25 mm/sec).
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of clinical deterioration pointed to verapamil as the
responsible drug. This hypothesis is supported given that
notonlydidthepatientbegincomplainingofweaknessand
dyspneawithin2hoursofthefirstandonlyverapamildose,
but he also presented with signs of cardiogenic shock with
bloodpressureof70/50mmHgandaheartrateof101beat/
min. A posteriori, verapamil appears as the likely “missing
link” between these apparently unrelated symptoms.
Indeed, bradycardia, transient asystole and exacerbation of
heart failure have been reported with verapamil, although
these responses usually occurred after intravenous adminis-
trationofthedrugorinthepresenceofb-adrenergicreceptor
blockade [6,12]. In this case, oral verapamil was added to
atenolol, potentially contributing to further acute myocar-
dial hemodynamic depression, as it has been frequently
reported in the past [6,12]. However, if further cardiac
deterioration upon exposure to verapamil was solely due to
itscalciumchannelblockingproperties,itshouldhavebeen
observed before, while the patient was on a combined
metoprololanddiltiazemregimen.Infact,inthiscase,afew
minutesbeforethe cardiogenic shock,a pacemaker-induced
sinus rhythm was recorded and spectacular widening of the
QRS (230 msec) was observed (Figure 1A), suggesting
further deterioration of cardiac conduction upon exposure
to verapamil. Interestingly, in addition to its calcium
channel-blocking properties, and unlike diltiazem, verapa-
mil has been reported toblockboththe fast andlatecardiac
sodiumcurrents[13,14].Inapatientsuchasours,forwhom
calcium-dependent depolarization is compromised, con-
duction capacity strongly relies on the cardiac sodium
current (INa). It is therefore likely that verapamil, with its
INa-blockingeffect,depletedthe“vitalconductionreserve”of
thispatient,leadingtocardiacdecompensationandshock.It
is noteworthy that this has never been observed with
diltiazem before due to lack of INa-blocking influence. QRS
narrowingfollowingverapamil withdrawal andadministra-
tion of calcium chloride and glucagon (Figure 1B) is also
consistent with this explanation. Nevertheless, one could
argue that diltiazem is also a CCB known to affect the NMT.
However, our patient had been treated safely withthisdrug,
wellbeforethe onsetofthe cardiac deterioration.Moreover,
as the elimination half-life of diltiazem is estimated at
5 hours, and as verapamil was initiated more than 24 hours
after diltiazem cessation, approximately 5 half-lives, it
appears unlikely that a significant combined calcium
channel blocking action of both drugs was responsible for
the patient’s neuromuscular and cardiac deterioration.
Another possible explanation for the clinically observed
rapid hemodynamic deterioration of this patient was the
development of Takotsubo syndrome. Takotsubo cardi-
omyopathy, also known as transient apical ballooning or
apical ballooning cardiomyopathy, is a type of nonis-
chemic cardiomyopathy in which there is a sudden
temporary weakening of the myocardium [15]. The
typical presentation of someone with Takotsubo cardio-
myopathy is sudden onset of congestive heart failure or
chest pain associated with ECG changes suggestive of an
anterior wall heart attack. During the course of evaluation
of the patient, a bulging out of the left ventricular apex
with a normo- or hypercontractile base of the left
ventricle is considered the hallmark of this syndrome.
Indeed, the diagnosis is made by the pathognomic wall
motion abnormalities, in which the base of the left
ventricle is contracting normally or is hyperkinetic while
the remainder of the left ventricle is akinetic or
dyskinetic. This is accompanied by the lack of significant
coronary artery disease that could explain the wall
motion abnormalities. Provided that the individual
survives the initial presentation, the left ventricular
function improves within 2 months.
An argument against the Takotsubo syndrome hypothesis
in this case is the fact that hypokinesis was shown to be
diffuse and in both ventricles. Bulging of the apex was
never observed. Moreover, only a few hours after
verapamil withdrawal, ventricular function improved.
Five days later, the ejection fraction returned to normal
as well as the patient’s electrocardiogram.
Conclusion
We described a patient with known MG with cardiogenic
shock following administration of verapamil, a drug
known to cause a deleterious impact on the NMT. This
case strongly suggests that caution is needed when
administering verapamil or other CCBs to MG patients
with impaired NMT, especially when AchR-Ab and the
antistriated muscle antibodies titres are positive.
Abbreviations
AChR-Ab, Acetylcholine receptor-antibodies; BID, Twice
daily; CCB, Calcium channel blocker; ECG, electrocardio-
gram; INa, cardiac sodium current; LES, Lambert-Eaton
Syndrome; MG, Myasthenia Gravis; NMJ, Neuromuscular
Table 1. Classes of drugs known to exacerbate Myasthenia Gravis
Antibiotics (aminoglycosides, polypeptides, tetracyclines)
Quinine and related drugs
Antirheumatic drugs
Cardiovascular drugs: beta-blockers, procainamide, quinidine
Anti-epileptics
Benzodiazepines
Neuroleptics
Anaesthetics
Analgesics
Corticosteroids
D-penicillamine
Antihistamines
Diuretics
Anticholinergics
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daily.
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